Biomea Fusion (NASDAQ:BMEA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.
Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $12.00 price target on the stock.
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference